The negative news keeps piling on for GlaxoSmithKline PLC’s respiratory franchise with Advair Diskus’ sales flagging because of increased competition and pricing pressure and the next-generation drug Breo Ellipta failing to make up the lost ground. Now, an important survival study on which GSK had pinned much of its long-term hopes for Breo failed to show a survival benefit versus placebo.
GSK had hoped the results of SUMMIT would improve the case for Breo (fluticasone/vilanterol), a once-daily inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA)...